What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that…
What is Nurix Therapeutics, Inc.'s P/E and P/B ratio?
Nurix Therapeutics, Inc. has a P/E ratio of 10.5 and a P/B ratio of 6.92.
What is Nurix Therapeutics, Inc.'s debt-to-equity ratio?
Nurix Therapeutics, Inc. has a debt-to-equity ratio of 0.07.
How much does Nurix Therapeutics, Inc. owe compared with what it owns?
Nurix Therapeutics, Inc. owes $0.25 for every $1 it owns (balance sheet May 2026), which is low.
What is Nurix Therapeutics, Inc.'s Positivity rank?
Nurix Therapeutics, Inc. is ranked #5,244 of 6,774 companies globally and #2,817 of 4,000 in United States on PositoAI, with a Positivity Score of 17,984.
Does Nurix Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Nurix Therapeutics, Inc..
Where can I read the latest news about Nurix Therapeutics, Inc.?
Recent headlines about Nurix Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Nurix Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Nurix Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.